0000899243-22-031193.txt : 20220915 0000899243-22-031193.hdr.sgml : 20220915 20220915195320 ACCESSION NUMBER: 0000899243-22-031193 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220913 FILED AS OF DATE: 20220915 DATE AS OF CHANGE: 20220915 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Grant Julie Papanek CENTRAL INDEX KEY: 0001673237 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40431 FILM NUMBER: 221246794 MAIL ADDRESS: STREET 1: 2765 SAND HILL ROAD CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER NAME: FORMER CONFORMED NAME: Grant Papanek Julie DATE OF NAME CHANGE: 20210518 FORMER NAME: FORMER CONFORMED NAME: Papanek Julie DATE OF NAME CHANGE: 20160427 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Day One Biopharmaceuticals, Inc. CENTRAL INDEX KEY: 0001845337 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 832415215 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 395 OYSTER POINT BLVD STE 217 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080-1930 BUSINESS PHONE: 206-913-4300 MAIL ADDRESS: STREET 1: 395 OYSTER POINT BLVD STE 217 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080-1930 FORMER COMPANY: FORMER CONFORMED NAME: Day One Biopharmaceuticals Holding Co LLC DATE OF NAME CHANGE: 20210209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-09-13 0 0001845337 Day One Biopharmaceuticals, Inc. DAWN 0001673237 Grant Julie Papanek 395 OYSTER POINT BLVD, SUITE 217 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2022-09-13 4 S 0 86644 24.39 D 9577001 I See Footnote Common Stock 2022-09-13 4 S 0 1003 25.01 D 9575998 I See Footnote Common Stock 2022-09-14 4 S 0 105727 23.68 D 9470271 I See Footnote Common Stock 2022-09-14 4 S 0 384 24.29 D 9469887 I See Footnote Common Stock 2022-09-15 4 S 0 47967 22.79 D 9421920 I See Footnote Common Stock 2022-09-15 4 S 0 3314 23.73 D 9418606 I See Footnote Common Stock 439358 I See Footnote Common Stock 362 I See Footnote The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 - $24.99, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or for any other purpose. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 - $25.06, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.25 - $24.23, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.28 - $24.29, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 - $23.52, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.55 - $24.01, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Act, or for any other purpose. Represents shares held by The Adam and Julie Grant Revocable Trust dtd October 13, 2017 of which the Reporting Person and her spouse are co-trustees. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Act, or for any other purpose. /s/ Nancy Levenson, Attorney-in-Fact 2022-09-15